Wanted: More Women to Become Financial Planners
A $12,000 Smartphone May Already Be in Your Pocket
Amazon to Turn Fan Fiction into a Money Maker with Kindle Worlds
Proxy Advisory Firm Fined $300K for Alleged Data Breach
NASDAQ: CORT
UPDATE: Piper Jaffray Downgrades Corcept Therapeutics to Neutral Following 1Q13 Earnings Report
Top Wall Street Analyst Downgrades: BBVA, Excelon, Weatherford and More
Piper Jaffray Downgrades Corcept Therapeutics (CORT) to Neutral
Corcept Therapeutics downgraded to Neutral from Overweight at Piper Jaffray
Corcept Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Corcept Therapeutics, Inc. (CORT) Posts Q1 loss of 10c/Share
Corcept Therapeutics reports Q1 adjusted EPS (10c), consensus (9c)
2 High Risk Biotech Stocks Under $2 That Could Yield A High Reward
New Programs Designed to Speed Up Approval Process a Key Factor in Biotech Industry's Growth in 2012
Drug Information Association to host a forum